Amyotrophic lateral sclerosis & frontotemporal degeneration · 2026
ALSUntangled #84 - ivermectin.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Helmold Benjamin, Armon Carmel, Benatar Michael, Bertorini Tulio, Bromberg Mark, Brown Andrew, Cadavid Javier Mascias, Carbunar Olimpia, Carter Gregory T, Crayle Jesse, Feldman Eva, Foucher Juliette, Glass Jonathan, Greenstein Ethan, Jhooty Sartaj, Jiang Nan, Kochen Noah Nathan, McDermott Christopher, Olby Natasha, Pattee Gary, Porter Devon, Premasari Alan, Rao Anusha, Ratner Dylan, Staats Kim, Tito Elia, Vieira Fernando, Wicks Paul, Bedlack Richard
Аннотация
ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). In this review, we explore the possibility of using ivermectin to slow ALS progression. Ivermectin's ability to modulate neuroinflammation and excitotoxicity give it plausible mechanisms for treating ALS, though it does not get into the brain very well. One preclinical study demonstrated that ivermectin lengthened lifespan within a mouse model of mSOD1 genetic ALS. This finding has not been replicated. The 2 PALS we found who had data comparing ALSFRS-R progression on and off ivermectin appeared to have no benefit from it. We found no trials of ivermectin in PALS. Ivermectin is low cost and generally well tolerated with most adverse effects being mild and transient, but serious side effects can rarely occur, and it has not been carefully studied in PALS. We cannot at present endorse ivermectin as an ALS treatment.